September 02, 2025

Meet the Team: Mashaal Dhir, MD, FACS

As the new Section Chief for Upper GI, HPB and endocrine surgery at Roswell Park Comprehensive Cancer Center, Mashaal Dhir, MD, FACS, is eager to share his mission-driven approach to working with patients and referring physicians alike to fight cancer.

Roswell Park Comprehensive Cancer Center

September 02, 2025

Implementation of an Electronic Health Record Alert to Improve Naloxone Coprescribing for Adult Patients With Cancer at Risk for Opioid Overdose

A quality improvement initiative has transformed naloxone coprescribing practices for cancer patients at risk of opioid overdose, addressing key safety concerns in opioid management (source: Ruano et al., 2022).

JADPRO

September 02, 2025

Use of Cemiplimab as Adjuvant Therapy for High-Risk Cutaneous Squamous Cell Carcinoma

The randomized phase III C-POST trial attempted to learn whether the standard-of-care treatment in advanced cutaneous squamous cell carcinoma—cemiplimab-rwlc, which blocks the PD-1/PD-L1 pathway—could...

The ASCO Post

September 02, 2025

Cancer-Induced Nerve Injury Identified as Driver of PD-1 Resistance Across Tumor Types

Researchers have uncovered that cancer cells degrade protective nerve coverings, causing cancer-induced nerve injury that can lead to chronic inflammation and resistance to anti–PD-1 immunotherapy, ac...

The ASCO Post

September 02, 2025

APP CROSS: A Novel Scoring System to Evaluate Advanced Practice Provider Clinical Rotation Requests in Oncology

Explore how Baptist MD Anderson Cancer Center is revolutionizing cancer care training for nurse practitioners and physician assistants through innovative solutions like the APP CROSS scoring system.

JADPRO

September 01, 2025

Lymphoma: CAR T Treatment Safe and Effective for Outpatients in Proper Settings

Research indicates outpatient liso-cel CAR T-cell therapy is safe and effective for lymphoma patients, led by Dr. Yuliya Linhares.

Baptist Health South Florida

August 27, 2025

Clinical Trials and Research for Mantle Cell Lymphoma

Dana-Farber Cancer Institute is at the forefront of research in mantle cell lymphoma. We seek to advance more effective treatment options and reduce treatment side effects for patients with mantle cell lymphoma.

Dana-Farber

August 27, 2025

Tafasitamab Combined With Lenalidomide and Rituximab Improved Outcomes in Relapsed or Refractory Follicular Lymphoma

Adding tafasitamab-cxix, an anti-CD19 monoclonal antibody, to lenalidomide and rituximab significantly prolonged progression-free survival in patients with relapsed or refractory follicular lymphoma, ...

The ASCO Post

August 26, 2025

Two ACS Studies Show Colorectal Cancer Screening and Early Diagnosis Have Soared in Adults Aged 45 to 49 Years

A pair of studies by the American Cancer Society show that increases in colorectal cancer screening in adults aged 45 to 49 years are resulting in rises in earlier-stage diagnosis—12% per year from 20...

The ASCO Post